Investors

The ReSyn team is seeking investors with a shared vision and passion, and valuable networks capable of growing the enterprise.

ReSyn Biosciences currently offers a portfolio of innovative magnetic microparticle products, MagReSyn®, designed to specifically address the requirements of bioseparation, mass spectrometry and proteomics sample preparation. The products aim to address key limitations in R&D workflows, including reproducibility and low throughput, by developing automated workflows, and enabling clinical mass spectrometry applications. We follow and active partnering and co-development programme, where new opportunities may be enabled with the proprietary technology platform.

Please contact Justin Jordaan to find out more about potential investment.

Why Invest?

TEAM
The company was founded by the original inventive team, ensuring transfer of knowledge and the relevant skills for new product development. The team have experience and knowledge in life-sciences research and development, including proteomics, biocatalysis, protein chemistry, and bioseparation.

INTELLECTUAL PROPERTY
ReSyn Biosciences has an exclusive license (and right to assignment) for intellectual IP  to the proprietary polymer microparticle technology developed and patented at the CSIR (WO2009057049; IN267234; US9574054; ES2595104; EP2205662; DK2205662; CN101874061; CA2703478; JP五四四二六二四).

COLLABORATION NETWORK
ReSyn Bio is involved in automating complex mass spectrometry workflows developed by leading proteomics scientists in the MSMed Horizon 2020 project, and enabling high-throughput sample preparation platforms to enable clinical proteomics. We are a member of the Biocapture consortium, developing new tools, “plastic antibodies”, for cancer screening.

IMPACT
Our products are being used to identify new mechanisms of disease, with the biggest impact in cancer research. Please review the product pages to see the most recent citations using our research reagents.

PIPELINE
ReSyn Bio has a pipeline of new products and diagnostic technologies under development, including potential OEM opportunities under evaluation.

INTELLECTUAL PROPERTY
ReSyn Biosciences has an exclusive license to the proprietary polymer microparticle technology developed and patented at the CSIR (WO2009057049; IN267234; US9574054; ES2595104; EP2205662; DK2205662; CN101874061; CA2703478; JP五四四二六二四). ReSyn Biosciences (Pty) Ltd is a biotechnology company founded by the technology inventors.

TERMS AND CONDITIONS
Products supplied by ReSyn Biosciences (Pty) Ltd are for research purposes only. ReSyn products are not to be used for diagnostic, therapeutic or commercial means any use resulting in monetary gain, including, but not limited to, incorporation in a kit, repackaging and re-formulation. Please enquire about sub-licenses for commercial use.